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Background: Diabetic nephropathy (DN) is the most common cause of end-stage renal failure. Although
angiotensin II receptor blockers (ARBs) can be used to attenuate proteinuria in DN patients, their efficacy remains
limited. This clinical trial aimed to evaluate the efficacy of Tripterygium wilfordii Hook F (TwHF) extract in the
treatment of type 2 diabetes mellitus (DM)-induced nephropathy.
Methods: A total of 65 DN patients with proteinuria levels ≥ 2.5 g/24 h and serum creatinine levels < 3 mg/dl were
enrolled in this six-month, prospective, randomized, controlled study. The patients were randomized into treatment
groups that received either 120 mg of TwHF extract per day for three months, followed by 60 mg per day for three
more months, or 160 mg of valsartan daily for six months. The urinary protein and estimated glomerular filtration
(eGFR) level were measured at one, three, and six months after the commencement of treatment. The primary
measure of treatment efficacy was a reduction in the 24-h urine protein level between baseline and the end of the
study, and the secondary measure of treatment efficacy was a reduction in the eGFR value.
Results: At the end of the treatment period, the mean urine protein level in the TwHF group was dramatically
decreased (4.99 ± 2.25 g/24 h vs 2.99 ± 1.81 g/24 h, p < 0.01), with decreases at one, three, and six months of 32.9%,
38.8%, and 34.3%, respectively. In contrast, the proteinuria in the valsartan group was not significantly attenuated,
and the decreases in urine protein levels at treatment months one, three, and six were 1.05%, 10.1%, and -11.7%,
respectively. The mean decrease in eGFR in the valsartan group was greater than that in the TwHF group (26.4% vs.
13.7%, respectively; p =0.067).
Conclusions: TwHF extract can reduce the urine protein level of DN patients and represents a novel, potentially
effective, and safe drug for the treatment of DN patients with proteinuria.
Trial registration: ClinicalTrials.gov: NCT00518362
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Angiotensin II receptor blocker (ARB)Background
Diabetes mellitus (DM) is a major public health issue in
China. With the rapidly changing lifestyle of the general
Chinese population, there is increasing concern that dia-
betes may become an epidemic [1]. The impact of dia-
betic nephropathy (DN) in China has been evidenced by
our previous studies, in which examinations of renal bi-
opsies revealed that the incidence of DN was 1.68-fold* Correspondence: zhihong–liu@hotmail.com
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reproduction in any medium, provided the orthe level over a decade previously [2]. DN has become a
common cause of end-stage renal disease (ESRD) in
China.
Persistent proteinuria is a hallmark of DN and an
independent risk factor for DN progression and DN-
related cardiovascular events [3]. Therefore, improve-
ment of proteinuria is as important as control of blood
glucose and blood pressure for patients with DN [4].
Several multicenter, prospective, randomized, controlled
clinical trials have confirmed that renin-angiotensin sys-
tem (RAS) blockades with angiotensin II receptorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tients with DN and may confer additional benefits for
renal function [5,6]. However, the efficacy of the cur-
rently available ARBs for attenuating proteinuria is in-
sufficient, particularly for DM patients who present with
extensive proteinuria and renal dysfunction. Therefore,
it is imperative to develop novel strategies to decrease
proteinuria to prevent the progression of DN.
Tripterygium wilfordii Hook F (TwHF) extract is a
traditional Chinese medicine that has been used for
many years in glomerulonephritis treatment and organ
transplantation [7,8], likely for its immunosuppressive
and anti-inflammatory effects [9]. Consistent with this
traditional use, Goldbach-Mansky and colleagues have
reported that TwHF extract is also effective and safe for
the treatment of rheumatoid arthritis [10]. Our recent
in vitro and in vivo studies have shown that triptolide
(the primary active component of the TwHF extract)
protects podocytes from injury [11,12] and ameliorates
the albuminuria exhibited by db/db mice, effects that
are likely due to its podocyte-protective and anti-
inflammatory effects [13].
We conducted a clinical trial to explore the use of
TwHF extract in the treatment of DN. This single-center,
prospective, randomized, controlled trial was conducted
from March 2007 to April 2010 and was registered at
ClinicalTrial.gov (identifier: NCT 00518362). The aim of
this study was to evaluate the efficacy and safety of TwHF
and valsartan for reducing proteinuria in DN patients.
Methods
Patient selection
The inclusion criteria were patients 30-65 years of age
with a diagnosis of type 2 DM, proteinuria (urine pro-
tein ≥ 2.5 g/24 h), and serum creatinine levels of < 3 mg/dl.
The diagnosis of DN was confirmed either by the
pathological examination of a renal biopsy performed
within six months prior to study enrollment or by the
presence of clinical manifestations (if a renal biopsy
was unavailable). The local ethics committee of Jinling
Hospital approved the protocol, and all the enrolled
patients provided written informed consent prior to
the study. The exclusion criteria included a diagnosis
of type 1 DM, nondiabetic kidney disease, liver func-
tion impairment (alanine aminotransferase or aspar-
tate aminotransferase levels > twofold the upper limit
of normal), a white blood cell (WBC) count < 3.0 × 109/L,
severe hypertension (blood pressure > 180/100 mmHg
and refractory to treatment), any infections within
one month prior to the study, or major cardiovascu-
lar and cerebrovascular events (angina pectoris, heart
failure, myocardial infarction, cerebral infarction, and
cerebral hemorrhage) within the six months prior to
the study [5,6,14].Treatment plan
During the two-week screening phase [6], patients with
hypertension continued to receive the standard anti-
hypertensive therapy. Patients who had been receiving
angiotensin-I-converting enzyme inhibitors or angiotensin-
II-receptor antagonists were administered alternative medi-
cations (diuretics, calcium-channel antagonists, alpha- or
beta-blockers, or a combination of these drugs) [5,6,14].
The blood pressure of all the patients was maintained at
< 140/90 mmHg [5]. The TwHF extract tablets used in this
study were manufactured from the same species
(Tripterygium wilfordii Hook F) as that used by Goldbach-
Mansky et al. [10]. This medicine (10 mg/tablet) was
produced by Jiangsu General Pharmaceuticals Co, Ltd,
Taizhou, China and was approved by the State Food and
Drug Administration (SFDA) of China.
The patients were randomly assigned to two groups.
The TwHF group received 120 mg of TwHF per day (one
40-mg tablet three times daily) for three months, followed
by 60 mg of TwHF per day (one 20-mg tablet three times
daily) for the remaining three months. The valsartan
group received 160 mg of valsartan per day (Novartis, two
80-mg capsules once daily) for six months.
During the first three months of TwHF treatment, if
liver function impairment or a WBC count < 3.0 × 109/L
occurred, the dose was decreased to 60 mg/d for one
week. If the patient recovered, then treatment with
60 mg/d TwHF continued. Otherwise, the treatment was
discontinued, and the patient was excluded from the
study. If a patient developed a severe infection, the
TwHF treatment was halted, and the patient was with-
drawn from this study. If the infection was resolved
within two weeks, then observation continued, but the
baseline information would be reevaluated. The dosage
of valsartan was decreased to 80 mg/d if either the
serum creatinine level increased by 50% and > 2 mg/dl
or severe hyperkalemia (K+ > 6.0 mmol/L) was observed.
The valsartan treatment was discontinued if the above
conditions were not controlled by additional treatments.
Patients in either group were also excluded from the
study if the treatment was discontinued for more than
three weeks for any reason.
Throughout the study, the patients received routine
care for DM, including measurements of glycosylated
hemoglobin (HbA1c) and fasting serum glucose concen-
trations. The goals of the DM treatment included the
maintenance of fasting blood glucose (FBG) levels
< 7.0 mmol/L, postprandial blood glucose (PBG) levels
< 10.0 mmol/L, and HbA1c levels < 7.0% [15]. Other
treatments, such as diuresis to improve edema and albu-
min infusions, were performed in parallel. However,
these treatments were discontinued at least three days
prior to the measurement of urinary protein level. No
restrictions on dietary salts or proteins were mandated.
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Follow-up evaluations were scheduled at one, three, and
six months after the randomization (or more frequently,
if necessary) to monitor blood pressure, laboratory mea-
surements, and adverse events, as well as to assess end
points. Two 24-h urine specimens were obtained over
two consecutive days at baseline and one, three, and six
months after randomization, and the two-day urine pro-
tein measurements were averaged. At baseline and at
each follow-up visit, the vital signs and laboratory test
results were evaluated, including complete blood count,
FBG, blood urea nitrogen (BUN), serum creatinine,
estimated glomerular filtration rate (eGFR), serum
potassium, serum aspartate aminotransferase, alanine
aminotransferase, urinalysis, and 24-h urine protein
levels. The 24-h urine protein levels were measured via
the trichloroacetic acid method using a photometer [16].
The serum creatinine concentrations were determined
by the Jaffe reaction [17]. The Modification of Diet in
Renal Disease (MDRD) formula was used to determine
the eGFR [18]. The HbA1c levels were measured with
high-performance liquid chromatography [19]. All the
other laboratory parameters were assessed using conven-
tional laboratory methods. The blood pressure was mea-
sured twice while the patient was seated, after at least
15 min of rest, using a standard mercury sphygmoman-
ometer and an appropriately sized cuff. The mean value
was calculated for each pair of measurements.
Renal dysfunction was indicated by a serum creatinine
level > 1.5 mg/dl, and the progression of renal dysfunc-
tion was defined as an increase in serum creatinine of
≥ 25% of the baseline value. The primary measure of
treatment efficacy was a reduction in the 24-h urine pro-
tein level from baseline until the end of the study period
(six months), and the secondary measure of efficacy was
a reduction in the eGFR [5,14]. The end points were
defined as a doubling of the serum creatinine concen-
tration, the development of ESRD, cardiovascular or
cerebrovascular events, or death [6]. The doubling of
serum creatinine was defined as a level at the end of the
study period that was twice the baseline level and higher
than 5 mg/dl. ESRD was defined as serum creatinine
> 6 mg/dl, eGFR < 15 ml/min/1.73 m2, or the necessity
of long-term dialysis [6].
We contacted the patients who did not return for clin-
ical visits to inquire about the reasons for their failure to
participate in follow-up, whether they had continued
taking the medication, and whether they had reached
the study end points.
Statistical analysis
In our pre-trial, the urine protein level in the TwHF
group decreased by 52.2%, whereas the level in the
valsartan group decreased by < 10%. A sample size of 46patients (23 per group) was estimated to be sufficient to
provide 80% statistical power to detect a two-sided level
of significance of 0.05 at the primary end point. The data
are expressed as the mean values ± standard deviation
(SD). Student’s t-test, paired t-test, and repeated-
measures analysis of variance (ANOVA) were used for
between-group comparisons with adjustment for base-
line values, as appropriate. Bonferroni correction was
performed in t-test analysis. The differences in the urine
protein, blood pressure, serum creatinine, serum albu-
min, and eGFR measurements between baseline and
after one, three, and six months of treatment were ana-
lyzed by paired t-test, and repeated measures ANOVA
was used for the comparisons between TwHF and
valsartan group during the follow-ups. The qualitative
data are expressed as percentages and were analyzed
using the chi-square (χ2) or Fisher’s exact test, as indi-
cated. The correlations between a decrease in the urine
protein level at the end of study period and the blood
pressure, urine protein, serum creatinine, and eGFR
measurements at baseline were analyzed using the bi-
variate correlations test. The multiple imputations
method and a “pessimistic” analysis were used to assess
the impact of missing values. The p-values reported were
two-sided, and a p-value < 0.05 was considered statisti-
cally significant. All the analyses were performed using
SPSS software (version 11.0, SPSS Inc., USA).
Results
Patient characteristics
A total of 106 patients were screened at enrollment, and
41 patients were excluded. The remaining 65 patients
were randomized to the TwHF group (34 patients) or
the valsartan group (31 patients) and were followed up
for at least six months. In the TwHF group, one patient
who presented with a WBC count < 2.5 × 109/L was
withdrawn from the study, and four other patients were
lost to follow-up. In the valsartan group, one patient was
withdrawn due to recurrent, severe hyperkalemia (K+ >
6.5 mmol/L), and four other patients were lost to follow-
up [Figure 1]. The baseline characteristics of the two
treatment groups were comparable [Table 1].
Clinical response and adverse events
The urine protein levels in the TwHF group decreased
dramatically throughout the follow-up period. The re-
ductions from baseline after one, three, and six months
of treatment were 32.9%, 38.8%, and 34.3%, respectively.
In contrast, the urine protein levels in the valsartan
group remained relatively stable, with reductions at
months one, three, and six of 1.05%, 10.1%, and -11.7%,
respectively (p < 0.001) [Figure 2A]. The changes in the
blood pressure, urine protein, serum albumin, serum
creatinine, and eGFR during the follow-up period are
65 patients underwent randomization
106 patients were screened
26 had laboratory tests outside of the  
acceptable range
11 had unacceptable medical histories
3 had used excluded medications or therapies
1 had a current infection
34 patients were assigned 
to receive TwHF treatment
31 patients were assigned to 
receive valsartan treatment
26 valsartan patients  
completed the study
1 patient had a severe adverse  
event (K+ > 6.5 mmol/L)
4 patients were lost to follow-up
1 patient had a severe adverse  
event (WBC count < 2.5×109/L)
4 patients were lost to follow-up
29 TwHF patients  
completed the study
Figure 1 Flowchart of the treatment of DN with TwHF or valsartan.
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changes in the serum albumin levels in the TwHF group
during the treatment. The mean decreases in eGFR
during the six-month treatment period were 26.4% in
the valsartan group and 13.7% in the TwHF group
(p =0.067) [Figure 2B].
At months three and six, the proportions of patients
exhibiting DN disease progression (as evidenced by
serum creatinine levels ≥ 25% higher than baseline) were
significantly lower in the TwHF group than in the
valsartan group (18.18% vs. 48.00% at month three, re-
spectively, p = 0.022 and 27.59% vs. 69.23% at month six,




Duration of DM (months)
Duration of DN (months)
ACEI or ARB treatment before the screening phase (n,%)
Systolic blood pressure (mmHg)







eGFR (ml/min/1.73 m2) 4
Serum creatinine > 1.5 mg/dl (%)
Urine protein (g/24 h)A reduction in urine protein ≥ 50% and an increase in
serum creatinine < 50% compared with baseline were ob-
served in 31.03% (9 of 29) of the TwHF patients com-
pared with 11.54% (3 of 26) of the valsartan patients
(p = 0.076). When the data from the TwHF and valsartan
groups were combined, a reduction in urine protein was
correlated with the baseline diastolic blood pressure
(P = 0.021, R = -0.33) but not with the baseline systolic
blood pressure, serum creatinine, urine protein, or
eGFR.
A total of ten patients (five in the TwHF group and
five in the valsartan group) failed to complete the
follow-up evaluations due to loss of contact or severeroups
wHF group Valsartan group p
20:14 17:14 0.805
51.9 ± 9.8 51.0 ± 8.9 0.784
126.9 ± 68.1 106.8 ± 57.3 0.270
33.8 ± 30.6 26.1 ± 28.4 0.277
17, 50% 10, 32.3% 0.208
140.6 ± 15.8 138.3 ± 17.1 0.515
81.6 ± 11.9 84.4 ± 11.1 0.233
6.04 ± 1.51 6.70 ± 1.62 0.092
6.26 ± 1.15 6.68 ± 1.26 0.202
33.0 ± 5.66 33.07 ± 4.74 0.988
6.08 ± 1.96 5.92 ± 2.21 0.702
1.85 ± 0.83 2.50 ± 2.10 0.111
1.92 ± 0.72 1.67 ± 0.62 0.117
3.07 ± 21.65 47.72 ± 20.34 0.377
70.6% 54.8% 0.210








































































Figure 2 Changes in the baseline 24-h urine protein and eGFR levels over the six months of TwHF and valsartan treatments. A: The
reductions in the urine protein levels of the available patients, expressed as the mean percentages of urine protein reduction compared with the
baseline levels; B: The mean reductions in the eGFR values of the available patients, expressed as the mean percentages of eGFR reduction
compared with the baseline. Each error bar represents the standard deviation from the mean value. The statistical analysis was performed using
repeated-measures ANOVA. (TwHF group vs. valsartan group).
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performed to assess the impact of the missing values.
The recalculated reductions in proteinuria from baseline
were 32.2%, 39.1%, and 34.1%, after one, three, and six
months of TwHF treatment, respectively, percentages















140.6 ± 15.8 138.4 ± 16.6 135.1 ± 14.3 139.4 ± 16.2 137.
Diastolic blood
pressure (mmHg)
81.6 ± 11.9 85.0 ± 10.8 79.8 ± 10.3 78.7 ± 10.3 79.1
Urine protein (g/24 h) 4.99 ± 2.25 4.15 ± 1.29 3.23 ± 2.57**# 3.92 ± 1.56 2.83 ±
Serum albumin (g/L) 33.0 ± 5.66 33.0 ± 4.69 33.2 ± 5.35 # 37.7 ± 4.25‡ 33.
eGFR (ml/min/1.73 m2) 43.07 ± 21.65 47.72 ± 20.34 38.82 ± 19.93 43.59 ± 17.41 40.23
* p < 0.05 vs. TwHF baseline; **p < 0.01 vs. TwHF baseline.
† p < 0.05 vs. Valsartan baseline; ‡ p < 0.01 vs. Valsartan baseline.
# p < 0.05 vs. Valsartan group at the same follow-up.lacking proteinuria data were omitted. The recalculated
reductions in eGFR from baseline were 6.75%, 8.71%,
and 14.8% in the TwHF group, compared with 6.40%,
18.5%, and 27.2% in the valsartan group after one, three,
and six months of treatment, respectively. The results of
the pessimistic analysis, which imputed the missingin the TwHF group and valsartan group during the











Time Group Time ×
Group
9 ± 14.6 138.6 ± 19.7 137.4 ± 14.4 141.9 ± 18.4 0.455 0.943 0.408
± 10.0 77.7 ± 8.8 79.5 ± 8.5 76.5 ± 10.5 † 0.03 0.574 0.253
1.57**# 3.59 ± 1.71 2.99 ± 1.81**# 4.40 ± 2.37 <0.001 0.115 0.001
9 ± 5.3 37.4 ± 4.64‡ 34.8 ± 5.49 36.3 ± 5.47‡ <0.001 0.368 <0.001


























Figure 3 The incidence of renal disease progression during the
follow-up period. *p = 0.022 and **p = 0.003 for the TwHF and
valsartan groups, respectively.





Any adverse event (n,%) 13 (38.3) 12 (38.7)
Vomiting (n,%) 1 (2.94) 0 (0.00)
Liver dysfunction (n,%) 3 (8.82) 0 (0.00)
Decrease in WBC count (n,%) 1 (2.94) 0 (0.00)
Photosensitive dermatitis (n,%) 0 (0.00) 1 (3.22)
Hyperkalemia (n,%) 8 (23.53) 10 (32.2)
K+ > 6.0 (n,%) 3 (8.82) 2 (6.45)
Doubling of serum creatinine (n,%) 0 (0.00) 1 (3.22)
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the TwHF patients, but equal to the last value for the
valsartan patients, indicated reductions in proteinuria of
29.0%, 38.8%, and 26.8% at one, three, and six months,
respectively. The proteinuria reductions in the TwHF
group were significantly greater than those in the
valsartan group. When the missing eGFR values were
imputed as half of their last observed value for the
TwHF patients, but equal to their last value for the
valsartan patients, the reductions in eGFR were 7.08%,
9.61%, and 20.3% in the TwHF group, compared with
5.21%, 15.4%, and 28.3% in the valsartan group at one,
three, and six months, respectively (p > 0.05).
The overall incidence of adverse events was 38.4% in
the TwHF group, which was nearly identical to the
38.7% incidence observed in the valsartan group.
Hyperkalemia necessitated a discontinuation of treat-
ment in one patient (3.22%) in the valsartan group.
Treatment was also discontinued for one patient (2.94%)
in the TwHF group due to a reduction in the WBC
count (< 2.5 × 109/L). Liver function impairment was ob-
served in three patients in the TwHF group. After their
TwHF dose was reduced to 60 mg per day, these three
patients recovered and finished the trial. Hyperkalemia
was observed in eight patients in the TwHF group (with
K+ > 6.0 mmol/L in three patients) and in ten patients in
the valsartan group (with K+ > 6.0 mmol/L in two pa-
tients). A doubling of the serum creatinine was found in
only one patient, who was in the valsartan group. There
were no deaths in either group during the follow-up
period [Table 3]. The anti-fertility effects of the TwHF
extract were not evaluated because the majority of the
patients were older than 50, and patients attempting to
conceive had been excluded from the study.
Discussion
DN is one of the most severe complications of type 2
DM and a major cause of ESRD. The urine protein levelnot only reflects the degree of renal injury but is also an
independent risk factor for the progression of renal dis-
ease to ESRD. Increasing numbers of clinical trials have
reported a strong association between the baseline level
of proteinuria and a decline in eGFR [5,6,20,21]. As a re-
sult, urine protein is an important prognostic predictor,
and decreased urine protein levels have been considered
as a goal of DN treatment.
There were growing evidences indicated that immuno-
logic and inflammatory mechanisms play important roles
in the development and progression of DN [22,23]. In-
flammatory cytokines such as IL-1, IL-6, IL-18, TNF-α,
TGF-β, and MCP-1 have been found to be involved in the
pathophysiological processes of DN [22]. High glucose
levels, abnormal hemodynamics, immune and inflamma-
tory reactions, and injury of the glomerular basement
membrane and podocytes constitute the pathophysio-
logical basis of proteinuria. Indeed, our previous studies
have revealed podocyte loss, foot process fusion, slit mem-
brane effacement, the absence of nephrin expression, and
the downregulation of WT1 in the glomeruli of DN pa-
tients [24,25]. In this regard, apart from strict glycemic
control [26], ARBs have been demonstrated to be an ef-
fective therapeutic modality for DN [5,6,14,27,28]. The ef-
ficacy of ARBs is likely due to their ability to block RAS,
to lower blood pressure, to suppress the expression of cer-
tain inflammatory cytokines [29], and to protect podocytes
[30,31]. Considering the side effects of these drugs, which
include hyperkalemia and increased serum creatinine, they
are not appropriate for all patients, at least at the currently
prescribed dosages. Thus, it is necessary to develop new
medications for DN patients with proteinuria.
Previously, we have explored that TwHF extract elicits
immune suppressive and anti-inflammatory effects,
whereas triptolide potently inhibits NF-κB and the activa-
tion of T lymphocytes, as well as promoting apoptosis in
activated T lymphocytes [9]. In addition, TwHF can at-
tenuate oxidative stress and inhibit the expression of cer-
tain inflammatory cytokines (TNF-α, IL-1β, IL-6, and
IFN-γ) [32]. More recently, we further demonstrated that
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aminonucleoside-induced injury both in vivo and in vitro,
in addition to preventing proteinuria in treated animals
[11]. We also found that in cultured murine podocytes,
triptolide pretreatment prevented the puromycin-induced
disruption of the actin cytoskeleton and microfilament-
associated synaptopodin, as well as preventing reductions
in nephrin and podocin expression [11,12]. Based on the
observed immunosuppressive, anti-inflammatory, and
podocyte-protective effects of TwHF extract, we tested the
efficacy of TwHF extract in treating diabetic db/db mice
and found that albuminuria was markedly attenuated,
which was accompanied by an amelioration of glome-
rular hypertrophy and podocyte injury after triptolide
treatment. In addition, we found that the effects of
triptolide on renal inflammation and oxidative stress were
more profound than those of valsartan [13].
Based on these findings, this prospective, randomized,
controlled clinical trial was designed to evaluate the clin-
ical therapeutic efficacy and safety of TwHF extract in
patients with DN. We found that the urine protein level
could be significantly reduced by TwHF extract. At the
end of the trial, the reduction of urine protein in the
TwHF group was 34.3%, which was significantly greater
than the valsartan group. In addition, the decline in kid-
ney function in the patients receiving TwHF treatment
tended to be smaller than that observed in the valsartan-
treated patients.
Interestingly, although the urine protein levels were
dramatically reduced in the TwHF group, the serum al-
bumin levels did not increase significantly. We speculate
that TwHF extract may interfere with the synthesis of al-
bumin; further studies are required to reveal the under-
lying mechanism.
In this study, an ARB (valsartan) appeared less effect-
ive in reducing urine protein levels compared with previ-
ous, multicenter trials [5,6]; the urine protein levels in
our valsartan group were reduced by only 1.05% and
10.1% at months one and three, respectively, and they
tended to increase at month six. This discrepancy might
be attributed to the following explanations: 1) seven pa-
tients could not tolerate the 160-mg/d valsartan dose
due to hyperkalemia and increased serum creatinine;
therefore, they switched to a lower dose of 80 mg/d. In
contrast, the participants in the RENAAL (losartan
100 mg/d) and IDNT (irbesartan 300 mg/d) trials toler-
ated higher doses of ARBs. 2) The RENAAL and IDNT
trials evaluated the efficacy of losartan or irbesartan ra-
ther than valsartan; the therapeutic efficacies of these
different ARBs might be distinct. 3) Our inclusion cri-
teria were different from those in the abovementioned
trials: our enrollment criterion for proteinuria was
≥ 2.5 g/24 h, and the mean urine protein was 4.15 ± 1.29
(2.51-7.65) g/24 h in the valsartan group, which wassignificantly higher than that in the RENAAL (urine al-
bumin/creatinine 1,237 ± 1,261 mg/g.cr) and IDNT (me-
dian urine protein 2.9 (1.6-5.4) g/24 h) trials. 4) This
study investigated the short-term efficacy of TwHF and
valsartan treatments with a follow-up period of six
months, which was significantly shorter than those of
the previous studies.
The target level of blood pressure was < 140/90 mmHg,
however, during the follow-ups, 35% patients in TwHF
group and 41% patients in valsartan group did not reach
the target level. This discrepancy might be mostly attrib-
uted to the high percentage (63%) of the patients suf-
fered from chronic renal insufficiency. Although the
blood pressure did not touch the target, the systolic
blood pressure and diastolic blood pressure levels be-
tween two groups either at the baseline or during the
follow-ups did not show significant difference. So it is
not a major factor that impacts the efficacy judgement.
Regarding eGFR, Nelson et al. have reported that dia-
betic Pima Indians with macroalbuminuria demon-
strated eGFR declines of only 1 ml/min/1.73 m2 per
month over a four-year period [33], in contrast to the
larger change in eGFR over the six-month study period
in this trial. This discrepancy might be attributed to the
proteinuria and serum creatinine levels of the patients of
this study, which were both significantly higher than
those in the Nelson et al. study. Moreover, most of the
patients enrolled in our trial were in the late stages of
DN, whereas in the study by Nelson et al., all of the pa-
tients presented with normal renal function.
Because ten patients were withdrawn from the present
study, we conducted several analyses to specifically as-
sess the impact of the missing data, including a multiple
imputations analysis and a pessimistic analysis of the
missing values. The qualitative and quantitative protein-
uria results of these two analyses were similar to those
of the primary analyses (with the missing values omit-
ted). We also recalculated the eGFR values using these
two methods. Based on these exploratory analyses, we
concluded that the missing values due to patient with-
drawal produced no significant impact on our conclu-
sions concerning the primary efficacy of the TwHF
extract treatment evaluated in this clinical trial.
In previous clinical trials of TwHF, the major adverse
events included nausea, vomiting, loss of appetite, de-
creased WBC count, and liver function impairment
[7,8]. Several Studies have reported the potential mecha-
nisms of hepatoxicity and leucopenia induced by TwHF
[34-36]. In this trial, we found that the TwHF extract
dose of 120 mg/d was well tolerated by the majority of
the patients. Although some adverse events occurred in
the TwHF group, their incidence was comparable to that
observed in the valsartan group. Previous clinical trials
have also reported detrimental effects of TwHF extract
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in female patients. However, these effects were not ob-
served in this trial, which was largely due to the older
age (> 50 years) of the majority of the female patients.
This trial was limited by the following factors: 1) it
was a single-center trial with a small sample size and a
relatively short follow-up period, 2) the treatment as-
signment was not blinded, 3) the rate of subject with-
drawal during the follow-up period was > 10%, and 4) a
reduction in the 24-h urine protein level was used as a
surrogate end point. Thus, a multicenter, blinded, long-
term study is needed to confirm the renoprotective ef-
fects of TwHF extract in patients with DN.
Conclusions
In conclusion, TwHF extract can reduce the urine protein
levels of patients with DN and thus represents a novel, po-
tentially effective, and safe renoprotective drug for the
treatment of DN. TwHF extract may play an important
role in multidrug regimens for the treatment of DN.
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